Tuberculosis is a re-emerging global health threat. The World Health Organization (WHO) has estimated that about one third of the world's population is infected with Mycobacterium tuberculosis. In 1991 the global incidence of tuberculosis was ∼8 million with ∼3 millions deaths, and this has not fallen over the past decade [1] . Fortunately, the majority of M. tuberculosis-infected people will never develop clinical disease. It is generally accepted that protection against tuberculosis is immune mediated, yet the correlates of protective immunity remain poorly understood. In addition to type 1 CD4 T helper cells, there is mounting evidence that CD8 T lymphocytes are involved in the immune response against mycobacteria [2] . b 2 -microglobulin (b 2 m) gene knockout mice that lack functional CD8 T cells have been shown to be more susceptible to M. bovis bacille Calmette-Guérin (BCG) and M. tuberculosis infection [3, 4] . Major histocompatibility complex (MHC) class
Tuberculosis is a re-emerging global health threat. The World Health Organization (WHO) has estimated that about one third of the world's population is infected with Mycobacterium tuberculosis. In 1991 the global incidence of tuberculosis was ∼8 million with ∼3 millions deaths, and this has not fallen over the past decade [1] . Fortunately, the majority of M. tuberculosis-infected people will never develop clinical disease. It is generally accepted that protection against tuberculosis is immune mediated, yet the correlates of protective immunity remain poorly understood. In addition to type 1 CD4 T helper cells, there is mounting evidence that CD8 T lymphocytes are involved in the immune response against mycobacteria [2] . b 2 -microglobulin (b 2 m) gene knockout mice that lack functional CD8 T cells have been shown to be more susceptible to M. bovis bacille Calmette-Guérin (BCG) and M. tuberculosis infection [3, 4] . Major histocompatibility complex (MHC) class I-restricted CD8 T lymphocytes specific for mycobacterial antigens have been observed in mouse models of tuberculosis [3, 4] as well as in humans [5] [6] [7] [8] [9] [10] . Production of interferon (IFN)-g appears to be an important feature of CD8 T cells. Mice immunized with plasmid DNA expressing mycobacterial 65-kDa heat shock protein were protected against challenge with virulent M. tuberculosis. Adoptive transfer of protection to naive mice was associated with IFN-g-producing CD8 T cells that predominated after immunization [11] . Similar findings were observed when IFN-g gene knockout mice were used, which underlines the importance of macrophage-activating type 1 cytokines in the control of M. tuberculosis infection [12] . Human CD8 T cells have also been reported to secrete IFN-g and tumor necrosis factor (TNF)-a on recognition of mycobacterial antigens [7] [8] [9] [10] .
CD8 T cells can kill infected cells via a granule-dependent mechanism involving granzymes and perforin [7, 10, 13] and can exert antimicrobial activity through the release of granulysin [13] . Recently, Cho et al. reported that MHC class Irestricted CD8 T cells were able to reduce the viability of intracellular M. tuberculosis [14] .
Relatively few epitopes in mycobacterial antigens have so far been identified for human CD8 T cells [15] . Here we set out to identify CD8 T cell epitopes in the antigen 85 (Ag85) complex, which comprise the major secreted antigens of M. tuberculosis and have been implicated in protective immunity against tuberculosis [16] . Horwitz et al. have shown that immunization of highly susceptible guinea pigs with secreted antigens induced Downloaded from https://academic.oup.com/jid/article-abstract/183/6/928/2191313 by guest on 03 January 2019 strong immune responses that gave significant protection against aerosol challenge with virulent bacilli [16] . Smith et al. have recently shown that BCG and M. tuberculosis were capable of activating and stimulating human CD8 T cells in vitro [10, 17] . Using anti-MHC class I blocking antibodies and positive selection with magnetic beads, they showed that stimulated CD8 T cells were able to kill mycobacteria-infected macrophages as well as targets infected with recombinant vaccinia viruses expressing Ag85A and Ag85B [10, 17] . Together with data from murine studies [18] , these data clearly show that the major secreted antigens of the Ag85 complex have access to the class I-processing pathway and that short peptide fragments can be presented to CD8 T cells.
We used a reverse immunogenetics approach [19] to search for potential epitopes restricted by HLA-B*35, which is relatively common in West Africa [20, 21] , and found 3 novel CD8 T cell epitopes in the Ag85 complex.
Subjects and Methods
Subjects. BCG-vaccinated healthy volunteers were recruited from the Blood Bank at the Royal Victoria Hospital in Banjul, Gambia. The presence of a BCG scar was confirmed, and, if one was present, blood was drawn after informed consent was obtained. Genotyping of HLA class I was done by polymerase chain reaction analysis, using sequence-specific primers [22] .
Computer algorithms for predicting potential cytotoxic T lymphocyte epitopes. The Internet service of BIMAS (Computational Bioscience and Engineering Laboratory, Bethesda, MD) [23] and EpiMatrix (in collaboration with A. DeGroot, Tuberculosis/Human Immunodeficiency Virus (HIV) Research Lab, Brown University, Providence, RI) [24] were used to scan amino acid sequences of M. tuberculosis Ag85A (Rv3804c), Ag85B (Rv1886c), and Ag85C (Rv0129c) [25] .
Peptides. Lyophilized peptides were purchased from Research Genetics. Peptides were dissolved in 400 mL of dimethyl sulfoxide, were diluted in 0.9% NaCl to a concentration of 10 mM, and were stored at Ϫ70ЊC. HLA-B*35-binding peptides HIV-1 SF2 Nef (aa 72-80) (4T6R) FPVTPRVPL and Epstein-Barr virus (EBV; strain B95.8) large tegument protein (TEGU; aa 1974-1982) HPLTNNL-PL [26] were used as positive controls. As the negative control for binding, we used peptide influenza A virus nucleoprotein (aa 265-273) ILRGSVAHK [27] . Fluorescein (FL)-labeled reference peptides, also obtained from Research Genetics, were synthesized as lysine derivatives of positive control peptides.
Peptide-binding assays by flow cytometry. Binding assays were performed, as described elsewhere [28, 29] , by using Tap-deficient RMA-S cells expressing human b 2 m and HLA-B*3501 (generously provided by M. Takiguchi, Center for AIDS Research, Kumamoto, Japan) [26, 28] . Cells were cultured for 16 h at 26ЊC to allow "empty" HLA class I molecules to accumulate on the cell surface. Cells were pulsed for 1 h at 26Њ C with 1 mM FL-labeled reference peptide FPVTPCK(FL)VPL, together with different concentrations of unlabeled peptide. Cells were then incubated for 3 h at 37ЊC and were washed once with cold PBS/0.3% (w/v) bovine serum albumin (BSA), and the geometric mean fluorescence intensity was measured immediately with a FACS Calibur flow cytometer (Becton Dickinson). Results were expressed as the percentage of inhibition of the maximum signal or as the concentration (mM) at which the maximum signal with the FL-labeled reference peptide was reduced by 50% (IC 50 ).
The stability of peptide-MHC complexes at the cell surface was determined, as described elsewhere [30] . Cells were incubated after the overnight cold pulse for 2-9 hours at 37ЊC, with a sample being taken every hour. Samples were kept on melting ice until surface staining could be performed for all samples simultaneously. Cells were washed with cold PBS/0.3% (w/v) BSA and were incubated for 0.5 h at 4ЊC with 5 mg/mL anti-HLA class I monoclonal antibody (MAb) w6/32 (generously provided by L. Barber, John Radcliffe Hospital, Oxford, UK). They were then washed twice and stained with 100 mg/mL fluorescein isothiocyanate (FITC)-labeled goat anti-mouse immunoglobulin polyclonal antibodies (Central Laboratory Blood Transfusion Service). Finally, the cells were washed once, and the geometric mean fluorescence intensity was measured immediately with a FACS Calibur flow cytometer (Becton Dickinson). Using h at 37ЊC as the starting point, we t p 2 expressed the stability of peptide-MHC complexes as the time required for 50% of the molecules to decay (DT 50 ).
In vitro expansion of peptide-specific CD8 T cells. Antigenspecific CD8 T cells were expanded from peripheral blood mononuclear cells (PBMC), as described elsewhere [31] . In brief, PBMC were pulsed with 50 mM peptide for 1 h at room temperature. Cells were cultured in RPMI 1640 supplemented with 10% autologous plasma, antibiotics, and 5 ng/mL recombinant human interleukin (IL)-7 (R&D Systems Europe). On day 3 and every 3-4 days thereafter, complete medium containing 10 U/mL recombinant human IL-2 (generously provided by R. Rombouts, Chiron Benelux B.V., Amsterdam) or 10% Lymphocult-T (Biotest) was added. Shortterm bulk cultures were further expanded by restimulation with peptide-pulsed and irradiated autologous PBMC or EBV-transformed B-lymphoblastoid cell line (B-LCL).
ELISPOT assay for IFN-g. Peptide-stimulated effector cells were incubated in 96-well nitrocellulose-backed plates (Millipore) for 2 days at 37ЊC/5% CO 2 , in the presence of peptide, purified protein derivative of tuberculin, or phytohemagglutinin. ELISPOT assays were performed as suggested by the manufacturer (Mabtech). In brief, the plates were initially coated with 15 mg/mL of mouse anti-human IFN-g MAb (1-D1K) and were extensively washed to remove unbound coating antibody. After incubation with cells, plates were washed 4 times with PBS containing 0.05% Tween 20 (Sigma) and twice with PBS. Biotinylated mouse antihuman IFN-g MAb (7-B6-1-biotin) was added at 1 mg/mL, and plates were incubated for 2 h at room temperature. The plates were washed as before and were incubated for a further 1 h at room temperature with 1 mg/mL of streptavidin alkaline phosphatase. The plates were washed again and were developed with chromogenic alkaline phosphatase substrate (Biorad). After 20 min, the plates were washed with tap water and were allowed to dry. IFNg spot-forming cells (SFCs) were counted by using a dissection microscope. As per convention, only spots with fuzzy borders were scored as SFCs [6, 32] .
HLA class I tetramers. Tetramers were synthesized, as described elsewhere [33, 34] . The class I heavy chain was modified at the COOH-terminus so as to contain a 15-aa substrate peptide for BirA-dependent biotinylation. After the heavy-chain fusion protein was refolded in the presence of b 2 m and a specific peptide ligand, the complexes were purified by fast protein liquid chromatography (Pharmacia) and were biotinylated with BirA. Streptavidin-phycoerythrin (PE)-conjugate was added in a 1:4 molar ratio, to allow the formation of tetrameric peptide-MHC complexes.
Fresh PBMC or peptide-stimulated effector cells were washed once with PBS/0.3% (w/v) BSA and were incubated with 10 mL of PElabeled tetramers for 20 min at 37ЊC. Subsequently, 5 mL of peridininchlorophyll protein (PerCP)-conjugated mouse anti-human CD8 (IgG 1 ; Becton Dickinson Immunocytometry Systems [BDIS]) was added, and cells were incubated for another 15 min at 4ЊC. Cells were washed twice, were resuspended in PBS with 4% paraformaldehyde, and were analyzed with a FACS Calibur flow cytometer (Becton Dickinson).
Intracellular analysis of cytokines by flow cytometry. Activated CD8 T cells from short-term bulk cultures were analyzed for intracellular IFN-g production in response to mycobacteria-derived peptides, essentially as described elsewhere [35] . In brief, short-term bulk cultures were harvested, and cells were incubated for 6 2 ϫ 10 6 h at 37ЊC/5% CO 2 , with 10 6 target cells pulsed with peptide. Target cells were autologous EBV-transformed B-LCL or RMA-S B*3501 cells. During the last 4 h, Brefeldin A (Sigma Chemical Co.) was added, to a final concentration of 10 mg/mL. Cells were harvested and were washed once with PBS/0.3% (w/v) BSA. BDIS reagents and protocols were used to perform intracellular staining of cytokines. Cells were incubated with FACS Lysing Solution (BDIS) and FACS Permeabilizing Solution (BDIS), according to the manufacturer's instructions. Subsequently, cells were stained by using the following antibodies-PerCP-conjugated mouse anti-human CD8 (IgG 1 ), PE-conjugated mouse anti-human CD69 (IgG 1 ), FastImmune FITC-conjugated mouse anti-human IFN-g (IgG 2a ), or FITC-conjugated TNF-a (IgG 2a )-and the corresponding isotype-and fluorescent conjugate-matched control reagents. Cali-BRITE beads and FACSComp software were used to optimize instrument settings before use. Data were acquired by using a FACS Calibur flow cytometer and were analyzed by using CellQuest software. Data were displayed as 2-color dot plots to determine the level of cytokine expression in activated (i.e., CD69 ϩ ) CD8 T cells. Cytotoxicity assays. Standard 51 chromium ( 51 Cr)-release assays were performed, as described elsewhere [10, 17] . Effector cells were tested at different effector-to-target (E:T) ratios on 
Results
Screening for binding to HLA-B*3501. By use of computer algorithms [23, 24] , M. tuberculosis H37Rv-derived sequences of Ag85 complex proteins were searched for HLA-B*35 peptide-binding motifs. Only peptides that contained a proline at position 2 as anchor residue were considered for testing [36] . In total, 23 peptides from the Ag85 complex were evaluated in this study, including overlapping 8-, 9-, and 10-mer peptides. The peptides originated from 5 different regions in the Ag85 complex.
The peptides were first tested for their ability to stabilize HLA-B*3501 molecules at a fixed and saturating concentration of 50 mM (figure 1). The positive control peptides HIV-1 SF2 Nef (aa 72-80) (4T6R) FPVTPRVPL and EBV TEGU (aa 1974-1982) HPLTNNLPL gave strong and reproducible inhibition of the maximum signal of the FL-labeled reference peptide. In total, 6 of 23 peptides inhibited 175% and were considered for further testing.
Binding characteristics of Ag85 complex peptides. Peptides were tested in 8 serial 2-fold dilutions, to determine the concentration at which they inhibited the signal of 1 mM FL-labeled reference peptide by 50% (IC 50 ; The stability of peptide-MHC complexes was measured by following HLA class I surface expression of peptide-pulsed RMA-S B*3501 cells over a 2-9-h period at 37ЊC. Stability is expressed as DT 50 (in hours), the incubation time required for 50% of the complexes to decay (table 1). The DT 50 of the previously described HLA-B*3501-restricted epitope HIV-1 SF2 Nef (aa 72-80) 4T6R was 17 h. In fact, during the 2-9-h period, hardly any reduction was observed in the level of HLA class I expression. Similar results were obtained for peptide Ag85 ABC MPVGGQSSFY and its 9-mer variant, for peptide Ag85C (aa 204-212), and for peptide Ag85B (aa 264-272), which all formed very stable complexes with HLA-B*3501 (table 1). MHC complexes with peptide Ag85A (aa 267-275) gradually disappeared during the observation period. The corresponding DT 50 value was 6.4-7.0 h (table 1). MHC complexes with peptide Ag85C (aa 268-276) were not very stable, as surface expression diminished in the first few hours of observation.
Three novel CD8 T cell epitopes in the Ag85 complex. Two healthy BCG-vaccinated HLA-B*35-positive donors were screened for reactivity toward peptides that had IC 50 values !1 mM and were able to form stable complexes. One donor responded to peptide Ag85ABC MPVGGQSSF and Ag85C (aa 204-212) in ELISPOT assays for IFN-g. The other donor also responded to the Ag85C peptide and had a weak response to peptide Ag85B (aa 264-272). The frequency of IFN-g SFCs for the Ag85C peptide was 45-73 SFCs/10 6 PBMC. Because both Ag85A (Rv3804c), Ag85B (Rv1886c), and Ag85C (Rv0129c), starting at the first methionine of the leader sequence [25] . Numbering is according to Ag85B in the event that identical sequences occur in all 3 members of the Ag85 complex. b Binding capacity to HLA-B*3501 is expressed as the concentration (mM) of peptide needed to inhibit binding of the fluorescein-labeled peptide to 50% (IC 50 ) [29] . c Stability of peptide-major histocompatibility complexes is expressed as the incubation time at 37ЊC required for 50% of the complexes to decay (DT 50 ) [30] . NS, nonstable. d The 4T6R sequence variant of HIV-1 SF2 Nef (aa 72-80). This peptide has been shown to bind to HLA-B*35 [26] .
donors recognized the Ag85C peptide, and because of the availability of sufficient blood of one B*35-positive donor, we decided to further characterize the cells responding to this peptide. A short-term bulk culture of PBMC that was repeatedly stimulated with the Ag85C peptide was stained with CD8-PerCP MAb and PE-labeled HLA-B*3501 tetramers (figure 2). A significant proportion of CD8 T cells was visualized with the Ag85C (aa 204-212)-B*3501 tetramers (3.48%), whereas staining with Ag85B (aa 264-272)-B*3501 tetramers that served as negative control showed hardly any positive cells (0.04%). No significant staining with the tetramers was observed when fresh unstimulated PBMC of the same donor were used (data not shown).
Peptide-stimulated bulk cultures were analyzed for antigenspecific cytokine production by flow cytometry (figure 3). CD8 T cells from short-term cultures stimulated with peptide Ag85C (aa 204-212) were able to produce both IFN-g and TNF-a. The number of activated (i.e., CD69 ϩ ) CD8 T cells producing IFN-g in response to peptide Ag85C (aa 204-212) was 22.0% when RMA-S B*3501 transfected cells were used, whereas only 0.8% of cells were positive when tested on target cells pulsed with a control peptide ( figure 3 ). Frequencies were 41.6% and 3.1% when tested with autologous target cells pulsed with peptide Ag85C (aa 204-212) and a control peptide, respectively. Similar results were obtained for TNF-a, albeit with slightly lower frequencies (data not shown). Short-term bulk cultures stimulated with peptide Ag85C (aa 204-212) were tested for cell-mediated cytotoxicity (figure 4). Significant lysis of macrophages pulsed with peptide Ag85C (aa 204-212) was observed, with comparable levels of killing when M. tuberculosis-infected macrophages were tested (figure 4). In a parallel experiment, positively selected CD8 T cells from a peptide-stimulated bulk culture (enriched from 14.6% to 74.9% by using Miltenyi magnetic beads) lysed control targets (with medium or pulsed with control peptide 4T6R) at low levels ( to , respectively) and displayed sig-9.6% ‫ע‬ 1.2% 14.8% ‫ע‬ 2.7% nificant lytic activity toward macrophages pulsed with peptide Ag85C (aa 204-212; ) or macrophages infected 50.6% ‫ע‬ 8.0% with BCG ( ). 37.2% ‫ע‬ 6.0% Although we do not characterize it in great detail, we also observed significant peptide-specific cytolysis for peptide Ag85ABC MPVGGQSSF and peptide Ag85B (aa 264-272) and reactivity in ELISPOT assays for IFN-g.
Discussion
On the basis of the fact that even a small virus such as HIV-1 can contain large numbers of T cell epitopes [37] , it is reasonable to expect that the mycobacterial proteome will contain a myriad T cell epitopes. So far, only a limited number of M. tuberculosis-derived human CD8 T cell epitopes have been described [15] . Recently, several HLA-A*0201-restricted epitopes were identified in Ag85A [38] and Ag85B [14, 39] . Here we set out to identify human CD8 T cell epitopes in proteins of the Ag85 complex that are restricted by HLA-B*35, which is one of the common Btypes in West Africa [20, 21] . By using a reverse immunogenetics approach [19, 23, 24] , we identified 23 peptides from 5 regions in the Ag85 complex that carried the HLA-B*3501 peptidebinding motif [26, 28, 36] . In vitro binding assays revealed 3 9-mer peptides from the Ag85 complex that bound with high affinity to HLA-B*3501 and displayed low dissociation rates of peptide-MHC complexes. IC 50 values and the stability of peptide-MHC complexes were similar to those published elsewhere for other immunogenic peptides [29, 30] . Further testing of peptide Ag85C (aa 204-212) showed that human CD8 T cells restimulated with this peptide in vitro could be visualized with HLA-B*35 tetramers and produced IFN-g and TNF-a. The latter findings are interesting in the light of the fact that studies in mice suggested the relevance of these macrophage-activating cytokines for the control of mycobacterial infection [11, 12] . Peptide-stimulated effectors and positively selected CD8 T cells were able to kill mycobacteria-infected macrophages, in agreement with our earlier observations [10, 17, 38] .
Lalvani et al. reported 2 epitopes in ESAT-6 but were unable to identify any HLA-B*07-, -B*35-, or -B*53-restricted epitopes in Ag85A or Ag85C [7] . Here we observed у3 HLA-B*35-restricted epitopes in proteins of the Ag85 complex. Possibly the testing of peptide pools with 20-mer peptides is not optimal for the identification of CD8 T cell epitopes [7] . On the other hand, the reverse immunogenetics approach we took may yield biased results, because epitopes without an obvious binding motif, i.e., with a low score according to the available algorithms, may not be identified. A systematic evaluation can be achieved only by using overlapping sets of peptides covering full-length protein sequences or by sequencing peptides eluted from MHC class I molecules of M. tuberculosis-infected cells.
Tuberculosis vaccines based on multiple T cell epitopes will be of value only if tailored to HLA types common in populations with a relatively high transmission rate of tuberculosis. Interestingly, HLA-B*35 is part of the so-called HLA-B7 supertype family [40] . Members of this family bind overlapping sets of peptides, which suggests that at least some of these peptides can be used for studying patients with related HLA types. In preliminary experiments, we observed that the 3 B*35-resticted epitopes also bound to some extent to another B7-supertype family member, HLA-B*5301 [40] , which is also common in West Africa [20, 21] .
The murine H-2L d allele has been shown to bind peptides with a motif that is similar to the B7 supermotif [36] . Denis et al. identified 3 20-mer peptides from Ag85A that were able to induce H-2L d -restricted CD8 T cells in BALB/c mice [18] . Interestingly, one peptide contained the sequence MPVGGQSSF, and one peptide overlapped 8 of 9 amino acid residues with the Ag85C peptide (aa 204-212). This mouse model may potentially be used to evaluate the in vivo effect of human CD8 T cell epitopes restricted by HLA B7-supertype alleles on the viability and spread of mycobacteria through the body, similar to the approach with HLA-A*0201 transgenic mice [39] .
Isoniazid effectively inhibits mycobacterial growth and is widely used as part of WHO's recommended strategy for treating tuberculosis patients. Wilson et al. have shown that isoniazid also induces the expression of fibronectin-binding protein C (fbpC2) or Ag85C [41] . The finding here of CD8 T cell epitopes in Ag85C suggests that the currently applied standard chemotherapy for tuberculosis may in fact also enhance the specific immune response against mycobacteria-infected cells.
Further characterization and identification of M. tuberculosis-specific CD8 T cell responses at the epitope level may help to elucidate the exact role of CD8 T cells in protection against tuberculosis and, we hope, may assist in the development of novel tuberculosis vaccines.
